Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Merck (MRK) Misses Q4 EPS by 6c, FY Guidance Tops Views
February 4, 2021 6:47 AM ESTMerck (NYSE: MRK) reported Q4 EPS of $1.32, $0.06 worse than the analyst estimate of $1.38. Revenue for the quarter came in at $12.5 billion versus the consensus estimate of $12.68 billion.
GUIDANCE:
Merck sees FY2021 EPS of $6.48-$6.68, versus the consensus of $6.41. Merck sees... More
